DATE: January 21, 2021 10:00 am - 3:00 pm EST
Acromegaly Community, Inc. invites you to an externally-led Patient Focused Drug Development (EL-PFDD). Due to COVID-19, this event will be held virtually.
The upcoming acromegaly externally led Patient-Focused Drug Development (PFDD) meeting is a groundbreaking initiative that will give acromegaly patients and their families the opportunity to provide the Food and Drug Administration (FDA), drug developers, and NPC stakeholders with perspectives from our community on a number of important issues.
The meeting will follow the successful model developed by the FDA for similar Agency-convened meetings and provide persons with acromegaly the unique opportunity to share their story and experiences—including the challenges they face–with senior FDA officials and industry to better inform how therapies are developed and how the Agency evaluates and considers potential therapies for the disease.
It’s mission is critical that all stakeholders (patients, physicians, pharmaceutical companies and the FDA) participate, which is why I’m asking for your support for this one-time momentous event.
Acromegaly Community wishes to thank the following companies for their support of our Patient Focused Drug Development program. Working together to improve the lives of patients. For this we say thank you for helping to make our voices heard.